Theranostics · 2017 · 196 citations · 38 references
MedicineCancer BiologyOncologyDrug DeliveryImmunoregulationTumor MicroenvironmentCancer ImmunotherapyCancer NanomedicineNanomedicineNanoparticle DesignTumor Immune MicroenvironmentTumor Microenvironment ModulationCancer NanotherapyImmunomodulatory CytokinesMesoporous Silica NanomaterialsMesoporous Silica NanoparticlesSilica-based NanoparticlesTumor Microenvironment EffectsTumor Microenvironment ResponsivenessTumor-targeted Drug Delivery
There is accumulating evidence that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Herein, to remodel tumor immune microenvironment and elicit synergistic antitumor effects, lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated combinational therapy provided a benign regulation on tumor microenvironment through activation of tumor infiltrating T lymphocytes and natural killer cells, promotion of cytokines secretion of IFN-γ and IL-12, and down-regulation of immunosuppressive myeloid-derived suppressor cells, cytokine IL-10 and TGF-β. ATRA/DOX/IL-2 co-loaded dHMLB demonstrated significant tumor growth and metastasis inhibition, and also exhibited favorable biodegradability and safety. This nanoplatform has great potential in developing a feasible strategy to remodel tumor immune microenvironment and achieve enhanced antitumor effect.
38
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière et al. · The Journal of Experimental Medicine · 2005 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke, Camilla Engblom, Steffen Rickelt et al. · Immunity · 2016 · 950 citations · Full text
Medicine, Immunology, Oncology +14